SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma - Quaterly Results

04 Aug 2025 Evaluate
The June 2025 quarter revenue stood at Rs. 28481.70 millions, up 15.78% as compared to Rs. 24600.90 millions during the corresponding quarter last year.The Profit  for the quarter ended June 2025 of  Rs. 5591.30  millions  grew by 69.93% from Rs. 3290.40 millions.OP of the company witnessed a marginal growth to 8801.10 millions from 5642.50 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 28481.70 24600.90 15.78 28481.70 24600.90 15.78 109333.00 106456.40 2.70
Other Income 837.70 653.20 28.25 837.70 653.20 28.25 3281.20 6160.60 -46.74
PBIDT 8801.10 5642.50 55.98 8801.10 5642.50 55.98 28856.90 28401.00 1.61
Interest 600.00 511.30 17.35 600.00 511.30 17.35 2300.40 1826.00 25.98
PBDT 8201.10 5131.20 59.83 8201.10 5131.20 59.83 26556.50 26575.00 -0.07
Depreciation 700.20 668.80 4.69 700.20 668.80 4.69 2972.00 2545.80 16.74
PBT 7500.90 4462.40 68.09 7500.90 4462.40 68.09 23584.50 24029.20 -1.85
TAX 1909.60 1172.00 62.94 1909.60 1172.00 62.94 6116.60 5028.20 21.65
Deferred Tax 32.80 -24.60 -233.33 32.80 -24.60 -233.33 -157.10 -952.60 -83.51
PAT 5591.30 3290.40 69.93 5591.30 3290.40 69.93 17467.90 19001.00 -8.07
Equity 580.80 585.90 -0.87 580.80 585.90 -0.87 580.80 585.90 -0.87
PBIDTM(%) 30.90 22.94 34.73 30.90 22.94 34.73 26.39 26.68 -1.07

Aurobindo Pharma Share Price

1385.65 -0.45 (-0.03%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×